Register for our free email digests:
GlaxoSmithKline Biologicals SA
Division of GlaxoSmithKline PLC
www.gsk.com
Latest From GlaxoSmithKline Biologicals SA
Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.
EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More
Biosimilar Litigation: Celltrion, Pfizer Claim Victory On Janssen’s Remaining Infringement Claim
Ensnarement defense bars Remicade maker from prevailing on claim that Inflectra partners infringed cell culture media patent, US federal judge rules.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
- Therapeutic Areas
- Cancer
- Infectious & Viral Diseases
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Benelux
-
Belgium
-
Belgium
-
Benelux
-
Western Europe
-
Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
- Jean Stephenne, Chmn. & Pres.
- Contact Info
-
GlaxoSmithKline Biologicals SA
Phone: (32) 2 656 81 11
Rue de L'Institute, 89
Rixensart, 1330
Belgium
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice